Preparation of stable and long-lived source samples for the stand-alone beam program at the Facility for Rare Isotope Beams

At the Facility for Rare Isotope Beams (FRIB), an oven-ion source combination was used to create rare isotope beams in support of the stand-alone user beam program of the ReAccelerator (ReA) facility. This ion source, called Batch-Mode Ion Source (BMIS), was loaded with enriched stable nuclides (30Si, 50Cr, and 58Fe) and long-lived radionuclides (26Al, 32Si). The introduced samples, herein designated as source samples, were thermally volatilized in the BMIS oven, and then ionization was used to generate the required beams. Owing to the different chemical behavior of the used samples, it was important to tailor the sample loading process for each desired beam species. An important parameter here is the volatility of the introduced species, which influences the adequate release of the isotope of interest. Additionally, any co-present, volatile components will affect the ion yields of the desired isotope, while isobaric contaminants will decrease the beam purity. To manufacture isotope source samples that meet these characteristics, various chemical methodologies were developed. All prepared samples were successfully used in BMIS to deliver beams for various user beam experiments. The here-established sample preparation techniques will greatly aid future efforts in developing offline rare-isotope beams.

Proof-of-concept studies of novel protocols for producing highly pure 48V from a 48Cr/48V generator

The quest to improve the quality of nuclear data, such as half-lives, transition yields, and reaction cross-sections, is a shared endeavor among various areas of nuclear science. ⁴⁸V is a vanadium isotope for which experimental data on neutron reaction cross-sections is needed. However, traditional isotope production techniques cannot produce ⁴⁸V with high enough isotopic purity for some of these measurements. "Isotope harvesting" at the Facility for Rare Isotope Beams (FRIB) is a new isotope production technique that could potentially yield ⁴⁸V with the necessary purity for such studies. In this case, ⁴⁸Cr would be collected and allowed to generate ⁴⁸V that can be separated from undecayed ⁴⁸Cr to yield highly pure ⁴⁸V. Thus, any protocol for producing pure ⁴⁸V via isotope harvesting would involve utilizing a separation technique that can effectively separate ⁴⁸Cr and ⁴⁸V. In this study, the radiotracers ⁵¹Cr and ⁴⁸V were used to develop possible radiochemical separation methodologies, which can be translated to obtain high purity ⁴⁸V via this novel isotope production method. The developed protocols utilize either ion exchange or extraction chromatographic resins. Separations of ⁵¹Cr and ⁴⁸V with AG 1-X8 anion exchange resin respectively resulted in recoveries of 95.6(26)% and 96.2(12)% with radionuclidic purities of 92(2)% and 99(1)%. An even more effective Cr and V separation was obtained with an extraction chromatographic resin (TRU resin) and 10 M HNO₃ loading solution. Here, ⁵¹Cr and ⁴⁸V respectively had recoveries of 94.1(28)% and 96.2(13)% with high radionuclidic purities (100(2)% and 100(1)%) in small volumes (8.81(8) mL and 5.39(16) mL). This study suggests that, to maximize the yield and isotopic purity of ⁴⁸V, the best production protocol would involve utilizing two separations with TRU resin and 10 M HNO₃ to isolate ⁴⁸Cr and purify the generated ⁴⁸V.

Harvesting 88Zr from heavy-ion beam irradiated tungsten at the National Superconducting Cyclotron Laboratory

Tungsten is a commonly used material at many heavy-ion beam facilities, and it often becomes activated due to interactions with a beam. Many of the activation products are useful in basic and applied sciences if they can be recovered efficiently. In order to develop the radiochemistry for harvesting group (IV) elements from irradiated tungsten, a heavy-ion beam containing ⁸⁸Zr was embedded into a stack of tungsten foils at the National Superconducting Cyclotron Laboratory and a separation methodology was devised to recover the ⁸⁸Zr. The foils were dissolved in 30% hydrogen peroxide, and the ⁸⁸Zr was chemically purified from the tungsten matrix and from other co-implanted radionuclides (such as ⁸⁵Sr and ⁸⁸Y) using strong cation-exchange (AG MP-50) chromatographic resin in sulfuric acid media. The procedure provided ⁸⁸Zr in approximately 60 mL 0.5 M sulfuric acid with no detectable radio-impurities. The overall recovery yield for ⁸⁸Zr was (92.3 ± 1.2)%. This proof-of-concept experiment has facilitated the development of methodologies to harvest from tungsten and tungsten-alloy parts that are regularly irradiated at heavy-ion beam facilities.

A Model for Radiolysis in a Flowing-Water Target during High-Intensity Proton Irradiation

At the Facility for Rare Isotope Beams (FRIB), interactions between heavy-ion beams and beam-dump water will create a wide variety of radionuclides which can be accessed by a technique known as "isotope harvesting". However, irradiation of water is always accompanied by the creation of numerous radical, ionic, and molecular radiolysis products. Some of the radiolysis products have sufficiently long lifetimes to accumulate in the irradiated water and affect the harvesting chemistry. Here we investigate the formation of hydrogen peroxide, molecular hydrogen, and molecular oxygen during a high-intensity proton irradiation of a flowing-water isotope-harvesting target and compare the experimental results to simulations. The simulations kinetically model the chemical reactions occurring in the homogeneous phase of radiolysis in flowing water and establish an "effective yield". In both the experiment and simulations, the bulk quantities of H₂, H₂O₂, and O₂ are considerably lower than predicted by primary radiolysis yields (escape yields), meaning that in the high beam intensity regime the homogeneous phase reactions have a considerable impact on the overall chemical composition of the water. Further, it could be shown that for radiation which is characterized by a limited linear energy transfer, such as the here applied protons, the bulk outcome of the microscopic kinetic modeling could be estimated by a simplified steady-state model.

Harvesting krypton isotopes from the off-gas of an irradiated water target to generate 76Br and 77Br

A flowing-water target was irradiated with a 150 MeV/nucleon beam of 78Kr at the National Superconducting Cyclotron Laboratory to produce 77Kr and 76Kr. Real-time gamma-imaging measurements revealed the mass transport of the krypton radioisotopes through the target-water processing, or “isotope harvesting”, system. The production rates were determined to be 2.7(1) × 10–4 nuclei of 76Kr and 1.18(6) × 10–2 nuclei of 77Kr formed per incident 78Kr ion. Utilizing an off-gas processing line as part of the isotope harvesting system, a total of 7.2(1) MBq of 76Kr and 19.1(6) MBq of 77Kr were collected in cold traps. Through the decay, the daughter radionuclides 76Br and 77Br were generated and removed from the traps with an average efficiency of 77 ± 12%. Due to the differences in half-lives of 76Kr and 77Kr, it was possible to isolate a pure sample of 76Br with 99.9% radionuclidic purity. The successful collection of krypton radioisotopes to generate 76Br and 77Br demonstrates the feasibility of gas-phase isotope harvesting from irradiated accelerator cooling-water. Larger-scale collections are planned for collecting by-product radionuclides from the Facility for Rare Isotope Beams.

Branching ratios for the three most intense gamma rays in the decay of 47Ca

A sample of ⁴⁷Ca produced through isotope harvesting at the National Superconducting Cyclotron Laboratory was used to measure branching ratios of 7.17(5)%, 7.11(5)%, and 75.0(5)% for the 489.2, 807.9, and 1297.1 keV characteristic gamma rays, respectively. Based on these updated branching ratios, the ground state to ground state ⁴⁷Ca to ⁴⁷Sc beta decay branching ratio has been indirectly measured as 17.7(5)% and the ground state to 1297.1 keV excited state as 82.2(5)%. These values represent a greatly increased precision for all five branching ratios compared to the currently accepted values (Burrows, 2007). The measurements presented here were made relative to the ingrown ⁴⁷Sc daughter in a⁴⁷Ca sample and the well-established 159.4 keV gamma-ray branching ratio and the half-life for the decay of ⁴⁷Sc (Reher et al., 1986; Meadows and Mode, 1968; Mommsen et al., 1980). These measurements were supported by verifying that the half-lives measured from characteristic gamma-ray peaks over multiple spectra for both ⁴⁷Ca and ⁴⁷Sc were consistent with previously reported values. Additionally, the half-lives of both ⁴⁷Ca and ⁴⁷Sc were independently measured with Liquid Scintillation Counting to reverify the previously reported values used in this study to find updated gamma-ray branching ratio values.

Production, Collection, and Purification of 47Ca for the Generation of 47Sc through Isotope Harvesting at the National Superconducting Cyclotron Laboratory

An experiment was performed at the National Superconducting Cyclotron Laboratory using a 140 MeV/nucleon ⁴⁸Ca beam and a flowing-water target to produce ⁴⁷Ca for the first time with this production route. A production rate of 0.020 ± 0.004 ⁴⁷Ca nuclei per incoming beam particle was measured. An isotope harvesting system attached to the target was used to collect radioactive cationic products, including ⁴⁷Ca, from the water on a cation-exchange resin. The ⁴⁷Ca collected was purified using three separation methods optimized for this work: (1) DGA extraction chromatography resin with HNO₃ and HCl, (2) AG MP-50 cation-exchange resin with an increasing concentration gradient of HCl, and (3) AG MP-50 cation-exchange resin with a methanolic HCl gradient. These methods resulted in ≥99 ± 2% separation yield of ⁴⁷Ca with 100% radionuclidic purity within the limits of detection for HPGe measurements. Inductively coupled plasma-optical emission spectrometry (ICP-OES) was used to identify low levels of stable ions in the water of the isotope harvesting system during the irradiation and in the final purified solution of ⁴⁷Ca. For the first time, this experiment demonstrated the feasibility of the production, collection, and purification of ⁴⁷Ca through isotope harvesting for the generation of ⁴⁷Sc for nuclear medicine applications.

Radiolysis and radionuclide production in a flowing-water target during fast 40Ca20+ irradiation

A flowing-water target was irradiated with a 140 MeV/u, 8 nA 40Ca20+ beam to test the feasibility of isotope harvesting at the upcoming Facility for Rare Isotope Beams. Among other radionuclides, 2.6(2)E-6 48Cr and 5.6(5)E-6 28 Mg nuclei were formed for every impingent 40Ca and were collected through ion exchange. Radiolysis-induced molecular hydrogen evolved from the target at an initial rate of 0.91(9) H2 molecules per 100 eV of beam energy deposited. No radiation-accelerated corrosion of the target material was observed.

Harvesting 62Zn from an aqueous cocktail at the NSCL

The radionuclide ⁶²Zn was obtained by “isotope harvesting” and separated from other co-produced species. The principle of a medical radionuclide generator was demonstrated by isolating pure ⁶²Cu, which is generated by the decay of its parent ⁶²Zn.

Radiomanganese PET Detects Changes in Functional β-Cell Mass in Mouse Models of Diabetes

The noninvasive measurement of functional β-cell mass would be clinically valuable for monitoring the progression of type 1 and type 2 diabetes as well as the viability of transplanted insulin-producing cells. Although previous work using MRI has shown promise for functional β-cell mass determination through voltage-dependent Ca²⁺ channel (VDCC)-mediated internalization of Mn²⁺, the clinical utility of this technique is limited by the cytotoxic levels of the Mn²⁺ contrast agent. Here, we show that positron emission tomography (PET) is advantageous for determining functional β-cell mass using ⁵²Mn²⁺ (t_1/2: 5.6 days). We investigated the whole-body distribution of ⁵²Mn²⁺ in healthy adult mice by dynamic and static PET imaging. Pancreatic VDCC uptake of ⁵²Mn²⁺ was successfully manipulated pharmacologically in vitro and in vivo using glucose, nifedipine (VDCC blocker), the sulfonylureas tolbutamide and glibenclamide (K_ATP channel blockers), and diazoxide (K_ATP channel opener). In a mouse model of streptozotocin-induced type 1 diabetes, ⁵²Mn²⁺ uptake in the pancreas was distinguished from healthy controls in parallel with classic histological quantification of β-cell mass from pancreatic sections. ⁵²Mn²⁺-PET also reported the expected increase in functional β-cell mass in the ob/ob model of pretype 2 diabetes, a result corroborated by histological β-cell mass measurements and live-cell imaging of β-cell Ca²⁺ oscillations. These results indicate that ⁵²Mn²⁺-PET is a sensitive new tool for the noninvasive assessment of functional β-cell mass.

Neodymium-140 DOTA-LM3: Evaluation of an In Vivo Generator for PET with a Non-Internalizing Vector

¹⁴⁰Nd (t_1/2 = 3.4 days), owing to its short-lived positron emitting daughter ¹⁴⁰Pr (t_1/2 = 3.4 min), has promise as an in vivo generator for positron emission tomography (PET). However, the electron capture decay of ¹⁴⁰Nd is chemically disruptive to macrocycle-based radiolabeling, meaning that an in vivo redistribution of the daughter ¹⁴⁰Pr is expected before positron emission. The purpose of this study was to determine how the delayed positron from the de-labeled ¹⁴⁰Pr affects preclinical imaging with ¹⁴⁰Nd. To explore the effect, ¹⁴⁰Nd was produced at CERN-ISOLDE, reacted with the somatostatin analogue, DOTA-LM3 (1,4,7,10- tetraazacyclododecane, 1,4,7- tri acetic acid, 10- acetamide N - p-Cl-Phecyclo(d-Cys-Tyr-d-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)d-Tyr-NH2) and injected into H727 xenograft bearing mice. Comparative pre- and post-mortem PET imaging at 16 h postinjection was used to quantify the in vivo redistribution of ¹⁴⁰Pr following ¹⁴⁰Nd decay. The somatostatin receptor-positive pancreas exhibited the highest tissue accumulation of ¹⁴⁰Nd-DOTA-LM3 (13% ID/g at 16 h) coupled with the largest observed redistribution rate, where 56 ± 7% (n = 4, mean ± SD) of the in situ produced ¹⁴⁰Pr washed out of the pancreas before decay. Contrastingly, the liver, spleen, and lungs acted as strong sink organs for free ¹⁴⁰Pr³⁺. Based upon these results, we conclude that ¹⁴⁰Nd imaging with a non-internalizing vector convolutes the biodistribution of the tracer with the accumulation pattern of free ¹⁴⁰Pr. This redistribution phenomenon may show promise as a probe of the cellular interaction with the vector, such as in determining tissue dependent internalization behavior.

Exploiting the Metal-Chelating Properties of the Drug Cargo for In Vivo Positron Emission Tomography Imaging of Liposomal Nanomedicines

The clinical value of current and future nanomedicines can be improved by introducing patient selection strategies based on noninvasive sensitive whole-body imaging techniques such as positron emission tomography (PET). Thus, a broad method to radiolabel and track preformed nanomedicines such as liposomal drugs with PET radionuclides will have a wide impact in nanomedicine. Here, we introduce a simple and efficient PET radiolabeling method that exploits the metal-chelating properties of certain drugs (e.g., bisphosphonates such as alendronate and anthracyclines such as doxorubicin) and widely used ionophores to achieve excellent radiolabeling yields, purities, and stabilities with 89Zr, 52Mn, and 64Cu, and without the requirement of modification of the nanomedicine components. In a model of metastatic breast cancer, we demonstrate that this technique allows quantification of the biodistribution of a radiolabeled stealth liposomal nanomedicine containing alendronate that shows high uptake in primary tumors and metastatic organs. The versatility, efficiency, simplicity, and GMP compatibility of this method may enable submicrodosing imaging studies of liposomal nanomedicines containing chelating drugs in humans and may have clinical impact by facilitating the introduction of image-guided therapeutic strategies in current and future nanomedicine clinical studies.

Mouse Positron Emission Tomography Study of the Biodistribution of Gold Nanoparticles with Different Surface Coatings Using Embedded Copper-64

By taking advantage of the ability of ⁶⁴Cu to bind nonspecifically to gold surfaces, we have developed a methodology to embed this radionuclide inside gold nanoparticles (AuNPs). ⁶⁴Cu enables the in vivo imaging of AuNPs by positron emission tomography (PET). AuNPs have a multitude of uses within health technology and are useful tools for general nanoparticle research. ⁶⁴Cu-AuNPs were prepared by incubating AuNP seeds with ⁶⁴Cu²⁺, followed by the entrapment of the radionuclide by grafting on a second layer of gold. This resulted in radiolabeling efficiencies of 53 ± 6%. The radiolabel showed excellent stability when incubated with EDTA for 2 days (95% radioactivity retention) and showed no loss of ⁶⁴Cu when incubated with 50% mouse serum for 2 days. The methodology was chelator-free, removing traditional concerns over chelator instability and altered AuNP properties due to surface modification. Radiolabeled ⁶⁴Cu-AuNP cores were prepared in biomedically relevant sizes of 20-30 nm and used to investigate the in vivo stability of three different AuNP coatings by PET imaging in a murine xenograft tumor model. We found the longest plasma half-life (T_1/2 about 9 h) and tumor accumulation (3.9%ID/g) to result from a polyethylene glycol coating, while faster elimination from the bloodstream was observed with both a Tween 20-stabilized coating and a zwitterionic coating based on a mixture of sulfonic acids and quaternary amines. In the in vivo model, the ⁶⁴Cu was observed to closely follow the AuNPs for each coating, again attributed to the excellent stability of the radiolabel.

Stable and high-yielding intrinsic (59) Fe-radiolabeling of the intravenous iron preparations Monofer and Cosmofer

Commercial iron supplements Monofer(®) and Cosmofer(®) were intrinsically radiolabeled with (59) Fe for the purpose of tracing iron absorption in vivo. Optimized procedures aimed at introducing (59) Fe into the macromolecular construct in a form that was as chemically equivalent to the matrix iron as possible. This was determined by challenging the labeled constructs with diethylenetriaminepentaacetic acid (DTPA) followed by separation by size-exclusion and measurements of radioactivity and iron in the eluted fractions. The final procedures were simple and involved heating aqueous dispersions of the supplements in the presence of [(59) Fe]FeCl3 for 24 h at 95 °C for Monofer, and 85 °C for Cosmofer, resulting in radiochemical yields greater than 94%. High performance size exclusion chromatography, UV-VIS spectroscopy, and dynamic light scattering were used to show that the supplements remained unchanged after radiolabeling, underscoring the applicability of the methodology for radiolabeling commercial iron preparations.

Novel Preparation Methods of (52)Mn for ImmunoPET Imaging

(52)Mn (t1/2 = 5.59 d, β(+) = 29.6%, Eβave = 0.24 MeV) shows promise in positron emission tomography (PET) and in dual-modality manganese-enhanced magnetic resonance imaging (MEMRI) applications including neural tractography, stem cell tracking, and biological toxicity studies. The extension to bioconjugate application requires high-specific-activity (52)Mn in a state suitable for macromolecule labeling. To that end a (52)Mn production, purification, and labeling system is presented, and its applicability in preclinical, macromolecule PET is shown using the conjugate (52)Mn-DOTA-TRC105. (52)Mn is produced by 60 μA, 16 MeV proton irradiation of natural chromium metal pressed into a silver disc support. Radiochemical separation proceeds by strong anion exchange chromatography of the dissolved Cr target, employing a semiorganic mobile phase, 97:3 (v:v) ethanol:HCl (11 M, aqueous). The method is 62 ± 14% efficient (n = 7) in (52)Mn recovery, leading to a separation factor from Cr of (1.6 ± 1.0) × 10(6) (n = 4), and an average effective specific activity of 0.8 GBq/μmol (n = 4) in titration against DOTA. (52)Mn-DOTA-TRC105 conjugation and labeling demonstrate the potential for chelation applications. In vivo images acquired using PET/CT in mice bearing 4T1 xenograft tumors are presented. Peak tumor uptake is 18.7 ± 2.7%ID/g at 24 h post injection and ex vivo (52)Mn biodistribution validates the in vivo PET data. Free (52)Mn(2+) (as chloride or acetate) is used as a control in additional mice to evaluate the nontargeted biodistribution in the tumor model.

The impact of weakly bound ⁸⁹Zr on preclinical studies: non-specific accumulation in solid tumors and aspergillus infection

Preclinical studies involving (89)Zr often report significant bone accumulation, which is associated with dissociation of the radiometal from the tracer. However, experiments determining the uptake of unbound (89)Zr in disease models are not performed as routine controls. The purpose of the present study was to investigate the impact of free or weakly bound (89)Zr on PET quantifications in disease models, in order to determine if such control experiments are warranted.

METHODS

Chemical studies were carried out to find a (89)Zr compound that would solubilize the (89)Zr as a weak chelate, thus mimicking free or weakly bound (89)Zr released in circulation. (89)Zr oxalate had the desired characteristics, and was injected into mice bearing FaDu and HT29 solid tumor xenografts, and mice infected in the lungs with the mold Aspergillus fumigatus, as well as in healthy controls (naïve). PET/CT or PET/MR imaging followed to quantify the distribution of the radionuclide in the disease models.

RESULTS

(89)Zr oxalate was found to have a plasma half-life of 5.1 ± 2.3 h, accumulating mainly in the bones of all animals. Both tumor types accumulated (89)Zr on the order of 2-4 %ID/cm(3), which is comparable to EPR-mediated accumulation of certain species. In the aspergillosis model, the concentration of (89)Zr in lung tissue of the naïve animals was 6.0 ± 1.1 %ID/g. This was significantly different from that of the animals with advanced disease, showing 11.6 ± 1.8 %ID/g.

CONCLUSIONS

Given the high levels of (89)Zr accumulation in the disease sites in the present study, we recommend control experiments mapping the biodistribution of free (89)Zr in any preclinical study employing (89)Zr where bone uptake is observed. Aqueous (89)Zr oxalate appears to be a suitable compound for such studies. This is especially relevant in studies where the tracer accumulation is based upon passive targeting, such as EPR.

Cyclotron produced ⁴⁴gSc from natural calcium

(44g)Sc was produced by 16MeV proton irradiation of unenriched calcium metal with radionuclidic purity greater than 95%. The thick target yield at saturation for (44g)Sc was 213 MBq/μA, dwarfing the yields of contaminants (43)Sc,(44 m)Sc, (47)Sc and (48)Sc for practical bombardment times of 1-2h. Scandium was isolated from the dissolved calcium target by filtration, and reconstituted in small volumes of dilute HCl. Reactions with the chelate 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) indicated a reactivity of 54 ± 14 Gbq/μmol at end-of-bombardment.

Very high specific activity ⁶⁶/⁶⁸Ga from zinc targets for PET

This work describes the production of very high specific activity (66/68)Ga from (nat)Zn(p,n) and (66)Zn(p,n) using proton irradiations between 7 and 16 MeV, with emphasis on (66)Ga for use with common bifunctional chelates. Principal radiometallic impurities are (65)Zn from (p,x) and (67)Ga from (p,n). Separation of radiogallium from target material is accomplished with cation exchange chromatography in hydrochloric acid solution. Efficient recycling of Zn target material is possible using electrodeposition of Zn from its chloride form, but these measures are not necessary to achieve high specific activity or near-quantitative radiolabeling yields from natural targets. Inductively coupled plasma mass spectroscopy (ICP-MS) measures less than 2 ppb non-radioactive gallium in the final product, and the reactivity of (66)Ga with common bifunctional chelates, decay corrected to the end of irradiation, is 740 GBq/μmol (20 Ci/μmol) using natural zinc as a target material. Recycling enriched (66)Zn targets increased the reactivity of (66)Ga with common bifunctional chelates.

ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW

CD105 (endoglin) is an independent marker for poor prognosis in more than 10 solid tumor types. The goal of this study was to develop a CD105-specific agent for both positron emission tomography (PET) and near-infrared fluorescence (NIRF) imaging, which has potential clinical applications in the diagnosis and imaged-guided resection of solid tumors. TRC105, a chimeric anti-CD105 monoclonal antibody, was conjugated to a NIRF dye (800CW) and p-isothiocyanatobenzyl-desferrioxamine (Df-Bz-NCS) before (89)Zr-labeling. Another chimeric antibody, cetuximab, was used as an isotype-matched control. FACS analysis revealed no difference in CD105 binding affinity/specificity between TRC105 and Df-TRC105-800CW. Serial PET imaging revealed that the 4T1 tumor uptake of (89)Zr-Df-TRC105-800CW was 6.3 ± 1.9, 12.3 ± 1.3, and 11.4 ± 1.1 %ID/g at 4, 24, and 48 h post-injection (p.i.) respectively (n = 3), higher than all organs starting from 24 h p.i., which provided excellent tumor contrast. Tumor uptake as measured by both in vivo and ex vivo NIRF imaging had a linear correlation with the %ID/g values obtained from PET, corroborated by biodistribution studies. Blocking experiments, control studies with (89)Zr-Df-cetuximab-800CW, and histology all confirmed the CD105 specificity of (89)Zr-Df-TRC105-800CW. In conclusion, herein we report dual-modality PET and NIRF imaging of CD105 expression in a breast cancer model, where CD105-specific uptake of (89)Zr-Df-TRC105-800CW in the tumor was observed.

Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW

Metastatic breast cancer is incurable. The goal of this study was to develop a positron emission tomography (PET)/near-infrared fluorescent (NIRF) probe for imaging CD105 expression in breast cancer experimental lung metastasis. TRC105, a chimeric anti-CD105 antibody, was dual-labeled with a NIRF dye (IRDye 800CW) and (89)Zr to yield (89)Zr-Df-TRC105-800CW. Luciferase-transfected 4T1 murine breast cancer cells were injected intravenously into female mice to establish the tumor model. Bioluminescence imaging (BLI) was carried out to noninvasively monitor the lung tumor burden. PET imaging revealed that 4T1 lung tumor uptake of (89)Zr-Df-TRC105-800CW was 8.7 ± 1.4, 10.9 ± 0.5, and 9.7 ± 1.1% ID/g at 4, 24, and 48 h postinjection (n = 4), with excellent tumor contrast. Biodistribution studies, blocking, control studies with (89)Zr-Df-cetuximab-800CW, ex vivo BLI/PET/NIRF imaging, and histology all confirmed CD105 specificity of the tracer. Broad clinical potential of TRC105-based agents was shown in many tumor types, which also enabled early detection of small metastasis and intraoperative guidance for tumor removal.

The unrealized potential of (34m)Cl for radiopharmaceutical research with PET

The unstable isotopes of chlorine have a brief history limited largely to production from sulphur isotopes. Recent improvements in accelerator targetry have made radiochlorine available from small cyclotrons, and concurrent research into labeling chemistry suggests both electrophilic and nucleophilic avenues for the synthesis of novel imaging probes. The prevalence of chlorine compounds from anthropogenic and natural sources offers varied and fertile ground for future scientific explanation with their radiolabeled counterparts.

Cross sections of the 36Ar(d,α)34mCl, 40Ar(d,α)38Cl, and 40Ar(d,p)41Ar nuclear reactions below 8.4 MeV

We have measured the cross section for production of the medically interesting isotope (34m)Cl, along with (38)Cl and (41)Ar, using deuteron bombardments of (36)Ar and (40)Ar below 8.4 MeV. ALICE/ASH analytical codes were employed to determine the shape of nuclear excitation functions, and experiments were performed using the University of Wisconsin tandem electrostatic accelerator to irradiate thin targets of argon gas.

Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105

PURPOSE

High tumor microvessel density correlates with a poor prognosis in multiple solid tumor types. The clinical gold standard for assessing microvessel density is CD105 immunohistochemistry on paraffin-embedded tumor specimens. The goal of this study was to develop an (89)Zr-based PET tracer for noninvasive imaging of CD105 expression.

METHODS

TRC105, a chimeric anti-CD105 monoclonal antibody, was conjugated to p-isothiocyanatobenzyl-desferrioxamine (Df-Bz-NCS) and labeled with (89)Zr. FACS analysis and microscopy studies were performed to compare the CD105 binding affinity of TRC105 and Df-TRC105. PET imaging, biodistribution, blocking, and ex-vivo histology studies were performed on 4T1 murine breast tumor-bearing mice to evaluate the pharmacokinetics and tumor-targeting of (89)Zr-Df-TRC105. Another chimeric antibody, cetuximab, was used as an isotype-matched control.

RESULTS

FACS analysis of HUVECs revealed no difference in CD105 binding affinity between TRC105 and Df-TRC105, which was further validated by fluorescence microscopy. (89)Zr labeling was achieved with high yield and specific activity. Serial PET imaging revealed that the 4T1 tumor uptake of (89)Zr-Df-TRC105 was 6.1 ± 1.2, 14.3 ± 1.2, 12.4 ± 1.5, 7.1 ± 0.9, and 5.2 ± 0.3 %ID/g at 5, 24, 48, 72, and 96 h after injection, respectively (n = 4), higher than all organs starting from 24 h after injection, which provided excellent tumor contrast. Biodistribution data as measured by gamma counting were consistent with the PET findings. Blocking experiments, control studies with (89)Zr-Df-cetuximab, and ex-vivo histology all confirmed the in vivo target specificity of (89)Zr-Df-TRC105.

CONCLUSION

We report here the first successful PET imaging of CD105 expression with (89)Zr as the radiolabel. Rapid, persistent, CD105-specific uptake of (89)Zr-Df-TRC105 in the 4T1 tumor was observed.

89Zr radiochemistry for positron emission tomography

The positron emitting isotope (89)Zr is an ideal radionuclide for use in positron emission tomography (PET) imaging with monoclonal antibodies (mAbs). This article reviews the cyclotron physics of (89)Zr production, and the chemical separation methods for isolating it from yttrium target material. (89)Zr coordination with the bifunctional chelate desferrioxamine B is discussed, along with the common procedures for attaching the chelate to mAbs. The review is intended to detail the procedure for creating (89)Zr labeled mAbs, going from cyclotron to PET.

HaloTag: a novel reporter gene for positron emission tomography

Among the many molecular imaging techniques, reporter gene imaging has been a dynamic area of research. The HaloTag protein is a modified haloalkane dehalogenase which was designed to covalently bind to synthetic ligands (i.e. the HaloTag ligands [HTL]). Covalent bond formation between the HaloTag protein and the chloroal-kane within the HTL occurs rapidly under physiological conditions, which is highly specific and essentially irreversible. Over the years, HaloTag technology has been investigated for various applications such as in vitro/in vivo imaging, protein purification/trafficking, high-throughput assays, among others. The goal of this study is to explore the use of the HaloTag protein as a novel reporter gene for positron emission tomography (PET) imaging. By attaching a HaloTag -reactive chloroalkane to 1, 4, 7-triazacyclononane-N, N', N"-triacetic acid (NOTA) through hydrophilic linkers, the resulting NOTA-conjugated HTLs were labeled with (64)Cu and tested for PET imaging in living mice bearing 4T1-HaloTag-ECS tumors, which stably express the HaloTag protein on the cell surface. Significantly higher uptake of (64)Cu-NOTA-HTL-S (which contains a short hydrophilic linker) in the 4T1-HaloTag-ECS than the non-HaloTag-expressing 4T1 tumors was observed, which demonstrated the HaloTag specificity of (64)Cu-NOTA-HTL-S and warranted future investigation of the HaloTag protein as a PET reporter gene.

A superconducting beta spectrometer

We have designed and constructed a superconducting beta spectrometer with a momentum resolution of about 2% and a peak solid angle of 0.5 sr. The performance of the spectrometer is described and the results of calibrations with line sources are presented.

Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase

We report the cloning and sequencing of a gene encoding the farnesyl pyrophosphate synthase of Trypanosoma cruzi. The protein (T. cruzi farnesyl pyrophosphate synthase, TcFPPS) is an attractive target for drug development, since the growth of T. cruzi is inhibited by carbocation transition state/reactive intermediate analogs of its substrates, the nitrogen-containing bisphosphonates currently in use in bone resorption therapy. The protein predicted from the nucleotide sequence of the gene has 362 amino acids and a molecular mass of 41.2 kDa. Several sequence motifs found in other FPPSs are present in TcFPPS. Heterologous expression of TcFPPS in Escherichia coli produced a functional enzyme that was inhibited by the nitrogen-containing bisphosphonates alendronate, pamidronate, homorisedronate, and risedronate but was less sensitive to the non-nitrogen-containing bisphosphonate etidronate, which, unlike the nitrogen-containing bisphosphonates, does not affect parasite growth. The protein contains a unique 11-mer insertion located near the active site, together with other sequence differences that may facilitate the development of novel anti-Chagasic agents.